伴有髓样化生的骨髓纤维化中的血管生成与抗血管生成治疗

Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.

作者信息

Arora Brijesh, Mesa Ruben, Tefferi Ayalew

机构信息

Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.

出版信息

Leuk Lymphoma. 2004 Dec;45(12):2373-86. doi: 10.1080/10428190400003267.

DOI:10.1080/10428190400003267

PMID:15621750

Abstract

Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest in hematological malignancies. This particular information has encouraged the therapeutic use of anti-angiogenic drugs in MMM. In the current review, we summarize the general concepts regarding angiogenesis, assessment of angiogenesis in hematological malignancies and then the current literature on angiogenesis and anti-angiogenic therapy in MMM.

摘要

骨髓纤维化伴髓样化生（MMM）是一种克隆性干细胞疾病，其特征为明显的骨髓基质反应，包括胶原纤维化、骨硬化和血管生成。几乎所有MMM患者的骨髓微血管密度（MVD）均升高，且升高程度在血液系统恶性肿瘤中位居前列。这一特殊信息促使抗血管生成药物在MMM治疗中的应用。在本综述中，我们总结了关于血管生成的一般概念、血液系统恶性肿瘤中血管生成的评估，以及目前关于MMM中血管生成和抗血管生成治疗的文献。